## IRON DISORDERS PANEL DG-4.3.0 (46 GENES)

Gene	Twist X2 covered 10x	Twist X2 covered 20x	srWGS covered 10x	srWGS covered 15x	srWGS covered 20x	Associated Phenotype description and OMIM disease ID
ABCB7	100%	100%	99.1%	91.4%	73.7%	Anemia, sideroblastic, with ataxia, 301310
ALAS2	100%	99.8%	97.5%	87.9%	70.7%	Anemia, sideroblastic, 1, 300751;Protoporphyria, erythropoietic, X-linked, 300752
ВМР6	100%	100%	100%	99.9%	98.7%	{Iron overload, susceptibility to}, 620121
CALR	100%	100%	100%	99.9%	98.3%	Myelofibrosis, somatic, 254450;Thrombocythe mia, somatic, 187950
CDAN1	100%	100%	100%	99.8%	97.7%	Dyserythropoietic anemia, congenital, type Ia, 224120
CDIN1	100%	100%	100%	99.9%	99.4%	Dyserythropoietic anemia, congenital, type lb, 615631
СР	100%	100%	100%	100%	99.6%	Aceruloplasminemia, 604290
CYBRD1	100%	100%	100%	99.8%	98.6%	

FECH	100%	100%	100%	99.9%	99.1%	Protoporphyria, erythropoietic, 1, 177000
FTH1	100%	100%	100%	99.8%	98%	Neurodegeneration with brain iron accumulation 9, 620669;?Hemochromat osis, type 5, 615517
FTL	100%	100%	100%	99.8%	98.2%	Hyperferritinemia- cataract syndrome, 600886;L-ferritin deficiency, dominant and recessive, 615604;Neurodegenera tion with brain iron accumulation 3, 606159

GATA1	100%	99.9%	97.8%	85.9%	67.2%	Anemia, congenital, nonspherocytic hemolytic, 9, 301083;Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 159595;Thrombocytope nia, X-linked, with or without dyserythropoietic anemia, 300367;Anemia, X-linked, with/without neutropenia and/or platelet abnormalities, 300835;Thrombocytope nia with betathalassemia, X-linked, 314050
GLRX5	100%	100%	100%	100%	99.5%	Anemia, sideroblastic, 3, pyridoxine-refractory, 616860;Spasticity, childhood-onset, with hyperglycinemia, 616859
HAMP	100%	100%	100%	100%	99.7%	Hemochromatosis, type 2B, 613313
HFE	100%	100%	100%	100%	98.9%	Hemochromatosis, type 1, 235200
HJV	100%	100%	100%	100%	98.6%	Hemochromatosis, type 2A, 602390

	1	1	1	1	1	1
HMOX1	100%	100%	100%	100%	98.7%	Heme oxygenase-1 deficiency, 614034;{Pulmonary disease, chronic obstructive, susceptibility to}, 606963
HSCB	100%	100%	100%	100%	99.1%	?Anemia, sideroblastic, 5, 619523
HSPA9	100%	100%	100%	100%	99.4%	Even-plus syndrome, 616854;Anemia, sideroblastic, 4, 182170
JAK2	100%	100%	100%	100%	99%	{Budd-Chiari syndrome, somatic}, 600880;Myelofibrosis, somatic, 254450;Erythrocytosis, somatic, 133100;Leukemia, acute myeloid, somatic, 601626;Thrombocythe mia 3, 614521;Polycythemia vera, somatic, 263300
KIF23	100%	100%	100%	100%	99.6%	Anemia, congenital dyserythropoietic, type IIIA, 105600

KLF1	100%	100%	100%	99.8%	97.1%	Blood groupLutheran inhibitor, 111150;[Hereditary persistence of fetal hemoglobin], 613566;Anemia, dyserythropoietic congenital, type IVa, 613673;Anemia, congenital dyserythropoietic, type IVb, 620969
LARS2	100%	100%	100%	100%	99.6%	Perrault syndrome 4, 615300;Hydrops, lactic acidosis, and sideroblastic anemia, 617021
LPIN2	99.6%	99.2%	100%	100%	99.3%	Majeed syndrome, 609628
MPL	100%	100%	100%	100%	98.5%	Myelofibrosis with myeloid metaplasia, somatic, 254450;Amegakaryocyt ic thrombocytopenia, congenital, 1, 604498;Thrombocythe mia 2, 601977
NDUFB11	99.4%	96.5%	90.9%	72.8%	53.8%	Linear skin defects with multiple congenital anomalies 3, 300952;?Mitochondrial complex I deficiency, nuclear type 30, 301021

PANK2	100%	100%	100%	100%	99.2%	Neurodegeneration with brain iron accumulation 1, 234200
PUS1	100%	100%	100%	100%	98.8%	Myopathy, lactic acidosis, and sideroblastic anemia 1, 600462
RACGAP1	100%	100%	100%	100%	99.5%	Anemia, congenital dyserythropoietic, type IIIb, autosomal recessive, 619789
SEC23B	100%	100%	100%	100%	99.5%	?Cowden syndrome 7, 616858;Dyserythropoiet ic anemia, congenital, type II, 224100
SF3B1	100%	100%	100%	100%	99.6%	Myelodysplastic syndrome, somatic, 614286
SFXN4	100%	100%	100%	100%	99.1%	Combined oxidative phosphorylation deficiency 18, 615578
SLC11A2	100%	100%	100%	100%	99%	Anemia, hypochromic microcytic, with iron overload 1, 206100
SLC19A2	100%	100%	100%	100%	99.8%	Thiamine-responsive megaloblastic anemia syndrome, 249270
SLC25A38	100%	100%	100%	100%	98.8%	Anemia, sideroblastic, 2, pyridoxine-refractory, 205950

SLC40A1	100%	100%	100%	100%	99.1%	Hemochromatosis, type 4, 606069
SLC46A1	100%	100%	100%	99.9%	98.1%	Folate malabsorption, hereditary, 229050
STEAP3	100%	100%	100%	99.9%	98.7%	?Anemia, hypochromic microcytic, with iron overload 2, 615234
TF	100%	100%	100%	100%	99.2%	Atransferrinemia, 209300
TFR2	100%	100%	100%	99.7%	97%	Hemochromatosis, type 3, 604250
TFRC	95.5%	95.5%	100%	99.7%	98.7%	Immunodeficiency 46, 616740
TMEM14C	100%	100%	100%	100%	99.8%	
TMPRSS6	100%	100%	100%	100%	98.2%	Iron-refractory iron deficiency anemia, 206200
TRNT1	91.9%	91.9%	100%	100%	99.6%	Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084;Retinitis pigmentosa and erythrocytic microcytosis, 616959
UROS	100%	100%	100%	100%	99.7%	Porphyria, congenital erythropoietic, 263700

YARS2	100%	100%	100%	100%	99.4%	Myopathy, lactic
						acidosis, and
						sideroblastic anemia 2,
						613561

Gene symbols used follow HGCN guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST X2 covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using TWIST X2 chemistry mapped against GRCh38.

TWIST X2 covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using TWIST X2 chemistry mapped against GRCh38.

srWGS covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38. srWGS covered 15x describes the percentage of a gene's coding sequence that is covered at least 15x when analyzed by WGS mapped against GRCh38. srWGS covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38. non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions: November 25th, 2024.

This list is accurate for panel version DG 4.2.0

Ad 1. Blank field signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors